The competition in the GLP-1 drug market intensifies as pharmaceutical giants Eli Lilly and Novo Nordisk vie for dominance with their injectable weight loss medications. Amazon’s entry into the market, selling GLP-1 pills, poses a significant challenge to established suppliers like Hims & Hers, WW International, and GoodRx. Initially, Novo Nordisk’s Wegovy led the market, but Eli Lilly’s Mounjaro and Zepbound have quickly gained traction. This shift marks a pivotal moment in the weight loss drug landscape.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
